Ozempic weight loss (Box of 4)

Ozempic (semaglutide) – Once-Weekly GLP-1 Receptor Agonist Injection

Ozempic is the leading once-weekly injectable prescription medication from Novo Nordisk, featuring semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative human GLP-1 analog (94% sequence homology to native GLP-1, with key modifications including Aib at position 8, lysine acylation at position 26 with a C18 fatty diacid spacer, and alanine-to-arginine substitution at position 34) provides sustained activation of GLP-1 pathways for enhanced glycemic control, cardiovascular protection, and renal benefits in adults with type 2 diabetes.

Administered subcutaneously via a user-friendly, pre-filled, single-patient-use pen, Ozempic mimics the effects of natural incretin hormones: it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and reduces appetite—helping lower blood sugar effectively when combined with diet and exercise.

Key Benefits & Clinical Effects:

• Proven A1C & Blood Sugar Reduction — Significantly lowers HbA1c and fasting/postprandial glucose levels in adults with type 2 diabetes, often achieving superior glycemic control compared to other therapies in clinical trials.
• Cardiovascular Risk Reduction — Lowers the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, or cardiovascular death, in adults with type 2 diabetes and established heart disease.
• Renal Protection — Reduces the risk of kidney disease progression, kidney failure (end-stage kidney disease), and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
• Weight Management Support — Frequently associated with meaningful body weight reduction (often 5–15%+ in studies) through appetite suppression, reduced caloric intake, and delayed gastric emptying—though Ozempic is not approved as a standalone weight-loss drug.
• Glucose-Dependent Mechanism — Minimizes hypoglycemia risk when used alone or without insulin/sulfonylureas, as effects are prominent only when blood glucose is elevated.

Product Highlights:

• Available in pre-filled, disposable pens delivering doses of 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection (various pen configurations for titration and maintenance).
• Clear, colorless to almost colorless, sterile solution; pH ≈7.4.
• Starting dose typically 0.25 mg once weekly for 4 weeks (to improve tolerability), then increased to 0.5 mg; further titration to 1 mg or 2 mg as needed for additional control (per healthcare provider guidance).
• Convenient once-weekly subcutaneous administration (abdomen, thigh, or upper arm), any time of day, with or without food—no reconstitution required.